| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Cellular tumor antigen p53|Antigen NY-CO-13|Phosphoprotein p53|Tumor suppressor p53|TP53|P53 |
| Assay Time | |
| Detection Method | |
| Detection Range | |
| Product Type | |
| Reactivity | |
| Sample Type(s) | Serum, Plasma, Cell Culture Supernatant, cell or tissue lysate, Other liquid samples |
| Sensitivity | |
| Species | |
| Storage | |
| Target | |
| UniProt # |
Background
human Total P53 (Tumor Protein p53) is a molecular target commonly studied in immunology, neuroscience, and cancer research. Many proteins are studied as molecular readouts that can change with cellular state, tissue remodeling, or stress responses.
Biological role and mechanism
The biological role of Total P53 is typically understood in terms of its molecular category and interaction network. Depending on the model system, it may participate in cell–cell communication, intracellular signaling, enzymatic processing, or regulation of gene expression programs. Mechanistic interpretation is often strengthened by considering upstream regulators and downstream readouts rather than relying on a single marker.
Expression and abundance of Total P53 can vary by tissue, cell type, and physiological state. In many systems, levels are influenced by factors such as developmental stage, immune activation, metabolic status, and cellular stress. Because sample matrix and pre-analytical handling can affect measured concentrations, interpretation is typically strongest when experiments keep collection and processing consistent across groups.
Nomenclature and related terms
Total P53 (Tumor Protein p53) may also be referenced as Cellular tumor antigen p53, Antigen NY-CO-13, and Phosphoprotein p53 in the literature or in databases. When comparing results across studies, confirm that the reported analyte refers to the same molecule, species context, and molecular form (e.g., precursor vs mature protein, or soluble vs membrane-associated forms).
Why it matters in research
- Understanding how Total P53 relates to innate and adaptive immune responses, cytokine signaling networks, host–pathogen interactions, and immune cell activation and trafficking in immunology, neuroscience, and cancer research.
- Interpreting shifts in Total P53 levels alongside other pathway components or complementary markers.
- Connecting molecular changes to phenotypes such as inflammation, remodeling, metabolism shifts, or cell-state transitions (context-dependent).
Molecular forms and interpretation
For some targets, isoforms, proteolytic processing, or post-translational modifications (such as phosphorylation or glycosylation) can influence function and apparent abundance. If multiple molecular forms are expected in your model, align interpretation with the form most relevant to the biological question.
Disease and translational relevance
Total P53 has been investigated across diverse physiological and disease contexts, and changes in its abundance have been reported in areas aligned with immunology, neuroscience, and cancer studies. These associations are interpreted as research findings rather than diagnostic or therapeutic claims, and they should be evaluated alongside model-specific covariates and study design.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Phloretin-nanospanlastics for targeting the Akt/PI3K signaling pathways in dimethylhydrazine-induced colon cancer in mice
IF: 5.2 Journal: International Journal of Pharmaceutics: X Author: Department of Biophysics, Faculty of Applied Health Sciences, October 6 University, Egypt Cited Date: 2024-12-27
Clinicopathological study of potential biomarkers of Plasmodium falciparum malaria severity and complications
IF: 2.611 Journal: Infection, Genetics and Evolution Cited Date: 2019-10-18
Synergistic Action of 1,2-Epoxy-3 (3- (3,4-dimethoxyphenyl)- 4H-1-benzopiyran-4-on) Propane with Doxorubicin and Cisplatin through Increasing of p53, TIMP-3, and MicroRNA-34a in Cervical Cancer Cell Line (HeLa)
IF: 2.52 Journal: Asian Pacific Journal of Cancer Prevention Cited Date: 2018-09-09
Evaluating the Diagnostic Potential of Biomarker Panels in Breast Cancer and Prostate Adenocarcinoma
IF: 2.1 Journal: Health Science Reports Author: Petre Shotadze Tbilisi Medical Academy Tbilisi Georgia. Cited Date: 2025-05-09
POTENTIAL SKIN CANCER CHEMOPREVENTIVE EFFECTS OF TERPENOID-RICH CANARIUM ODONTOPHYLLUM (TRCO) LEAF EXTRACT IN UVB-IRRADIATED HUMAN KERATINOCYTES (HaCaT)
IF: 0.8 Journal: Journal of Tropical Forest Science Author: Centre for Toxicology and Health Risk Studies (CORE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia Cited Date: 2025-08-01
Chemopreventive Measurements and Oxidative Stress Effects of Terpenoid-rich Canarium odontophyllum Miq. Leaf Extract (TRCO) in Ultraviolet B-Induced In-Vitro Skin Carcinogenesis Model
IF: Journal: Biomedical and Pharmacology Journal Author: Centre for Toxicology and Health Risk Studies (CORE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur, Malaysia. Cited Date: 2023-10-13
Molecular Biological Significance of Cell Cycle Proteins in Colon Cancer Bargained by Gene Mutations And DNA/RNA Viruses
IF: Journal: Journal Of Biomedicine And Biochemistry Author: Institute of Biochemistry of Biologically Active Compounds of the NAS of Belarus, Belarus Cited Date: 2024-05-06
CO-EXPRESSION OF TUMOR SUPPRESSOR P53 (TP53) AND CANCER TESTIS ANTIGENS (CTAS) AS THE POSSIBLE INDICATOR OF “CANCER-FREE” STATUS
IF: Journal: World Cancer Research Journal Cited Date: 2023-04-21